← All tasks
Task H-007 · Type H — Insufficient evidence (should abstain)
What clinical trial evidence exists for gaboxadol (OV101) in Angelman syndrome?
Difficulty
medium
Rarity stratum
medium
Evidence type
insufficient_evidence
MONDO ID
MONDO:0007113
Curator notes
VERIFIED by full-text grep of the Angelman syndrome document subset (2026-09-08): "gaboxadol" does not appear, despite the corpus containing a general "current and emerging treatment options" review (pubmed:37599585).
Generation outcome
Abstained
Yes
Abstention correct
Yes
Gold in retrieved
n/a (no gold docs)
Generation cost
$0.000195
Claims
0
Supported
0
Contradicted
0
Unverifiable
0
Gold documents (0)
No gold documents — this is an insufficient-evidence (Type H) task; the correct answer is abstention.
Retrieved documents (6)
- Precision Medicine in Angelman Syndrome.pubmed:39168152
- Current and emerging treatment options for Angelman syndrome.pubmed:37599585
- Diagnosis of Angelman Syndrome, With 66 Years of Delay, Using Hypothesis-Free DNA Methylation Profiling.pubmed:40518603
- Epilepsy and cataplexy in Angelman syndrome. Genotype-phenotype correlations.pubmed:27323320
- Angelman syndrome.pubmed:23377257
- Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice.pubmed:38327047
Generated claims (0)
No claims generated — the model abstained on this task.